PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-118992 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET
7.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Qiagen NV
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Pfizer
16.3 F Hoffman La Roche
16.4 GE Healthcare
16.5 Leica Biosystems Nussloch GmBH
16.6 Agilent Technologies
16.7 Thermo Fisher Scientific Inc.
16.8 Foundation Medicine
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypePCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
By Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Companies
Qiagen NV
Pfizer
F Hoffman La Roche
GE Healthcare
Leica Biosystems Nussloch GmBH
Agilent Technologies
Thermo Fisher Scientific Inc.
Foundation Medicine
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.